Medical Marijuana for Ehlers-Danlos Syndrome in Florida
Connective tissue disorders causing joint hypermobility, chronic pain, and fragility.
Medically reviewed by Bruce Stratt, MD
Board-Certified Physician · OMMU Certified · Boca Raton, FL
Overview
Ehlers-Danlos Syndrome (EDS) refers to a group of inherited connective tissue disorders characterized by defects in collagen structure and function. The most common form, hypermobile EDS (hEDS), causes joint hypermobility, chronic joint dislocations, widespread musculoskeletal pain, skin fragility, and often co-occurring conditions including POTS (postural orthostatic tachycardia syndrome), gastrointestinal dysfunction, mast cell activation syndrome, and migraines. Other forms of EDS can cause vascular fragility, severe skin laxity, and organ complications.
EDS is a chronic, lifelong condition with no cure. Pain management is one of the most significant challenges — EDS patients often experience daily pain from subluxations, muscle spasms, and nerve compression that is resistant to conventional analgesics. The average EDS patient has over 6 secondary conditions simultaneously, creating a complex clinical picture. Opioids carry particular risks for EDS patients due to the chronic nature of the condition and the risk of long-term dependency — patients may live with EDS for decades, making sustainable pain management approaches essential.
EDS qualifies for medical marijuana in Florida under the chronic pain and "comparable conditions" provisions of Statute 381.986. A survey found that 37% of EDS patients in the US already use cannabis therapeutically, reflecting widespread recognition of its benefits in the EDS community.
How Medical Cannabis May Help
Medical cannabis offers a multi-targeted approach to EDS symptom management, and emerging research specifically in EDS patients is encouraging. A study from the UK Medical Cannabis Registry (Dickinson et al., ACR Open Rheumatology, 2025) followed 161 patients with hypermobility spectrum disorder and hEDS over 18 months. Statistically significant improvements were found in pain severity and interference, sleep quality, and general health-related quality of life (all P<0.001). Anxiety scores also decreased significantly, and no significant safety concerns emerged at 18 months. Additional real-world evidence from the UK's Project Twenty21 registry (Stafford et al., 2025) followed 121 hEDS/HSD patients and reported clinical improvements across pain, sleep, and quality of life at up to 12 months. A published BMJ case report (Dempsey et al., 2021) described an 18-year-old woman with hEDS whose pain levels "considerably subsided" within days of starting medical cannabis — within three months, she had discontinued all opioid medications entirely. Cannabinoids reduce pain through both central and peripheral mechanisms, relax the muscle spasms that contribute to joint instability and pain, and modulate inflammatory processes in soft tissue. Both oral and topical formulations are valuable for EDS — topicals can be applied directly to painful joints for localized relief, while oral forms provide systemic benefits for widespread pain and co-occurring symptoms like anxiety, sleep disruption, and gastrointestinal dysfunction. Dr. Stratt develops comprehensive treatment plans that account for the full spectrum of EDS symptoms and comorbidities.
Individual results vary. Consult with Dr. Stratt to understand how cannabis therapy may apply to your specific situation.
What to Bring to Your Appointment
Bring a valid Florida ID and genetics or rheumatology records documenting EDS diagnosis, any relevant imaging or specialist reports, and your current medication list.
Frequently Asked Questions
Related Articles
Patient Resources
Get Your Medical Marijuana Card for Ehlers-Danlos Syndrome
Schedule your evaluation with Dr. Stratt. Same-day state registry submissions for qualifying patients.